C3 and acute respiratory distress syndrome: Among these new antagonists, Cp40, an analog of the peptide inhibitor of C3, compstatin, showed strong efficacy in several models of human diseases, such as sepsis (26), hemorrhagic shock (27), periodontal disease (28, 29), nocturnal paroxysmal hemoglobinuria (30), hemodialysis-induced inflammation (31), glomerulopathy C3 (C3G) (24), acute respiratory distress syndrome (ARDS) of COVID-19 (32), and cobra envenomation (33).